Apellis Pharmaceuticals, Inc. (APLS)
NASDAQ: APLS · Real-Time Price · USD
40.99
+0.04 (0.10%)
At close: Apr 28, 2026, 4:00 PM EDT
40.99
0.00 (0.00%)
After-hours: Apr 28, 2026, 4:38 PM EDT
Apellis Pharmaceuticals Stock Forecast
Stock Price Forecast
The 17 analysts with 12-month price forecasts for Apellis Pharmaceuticals stock have an average target of 33.59, with a low estimate of 18 and a high estimate of 52. The average target predicts a decrease of -18.05% from the current stock price of 40.99.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Apellis Pharmaceuticals stock from 21 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 6 | 6 | 6 | 4 |
| Buy | 7 | 6 | 5 | 5 | 5 | 1 |
| Hold | 9 | 8 | 8 | 8 | 9 | 15 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Total | 21 | 20 | 20 | 20 | 21 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $26 → $41 | Buy → Hold | Downgrades | $26 → $41 | +0.02% | Apr 17, 2026 |
| Mizuho | Mizuho | Hold Maintains $20 → $41 | Hold | Maintains | $20 → $41 | +0.02% | Apr 2, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Apr 1, 2026 |
| JP Morgan | JP Morgan | Buy → Hold Downgrades $37 → $41 | Buy → Hold | Downgrades | $37 → $41 | +0.02% | Apr 1, 2026 |
| Barclays | Barclays | Hold Maintains $24 → $41 | Hold | Maintains | $24 → $41 | +0.02% | Apr 1, 2026 |
Financial Forecast
Revenue This Year
882.48M
from 1.00B
Decreased by -12.08%
Revenue Next Year
1.04B
from 882.48M
Increased by 18.19%
EPS This Year
-1.18
from 0.17
EPS Next Year
-0.26
from -1.18
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 1.0B | 1.2B | ||||||
| Avg | 882.5M | 1.0B | ||||||
| Low | 778.6M | 855.6M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.1% | 40.4% | ||||||
| Avg | -12.1% | 18.2% | ||||||
| Low | -22.4% | -3.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.40 | 1.05 | ||||||
| Avg | -1.18 | -0.26 | ||||||
| Low | -2.15 | -1.98 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.